Dyslipidemia Drugs Market to Hit 5.27% to 2021: Growth Analysis, Company Profiles & Trends

Dyslipidemia Drugs Market is Projected to grow at 5.27% CAGR during the period 2017-2021. Network Consulting Industry research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.

Marketsizeforecasters.com adds new global Dyslipidemia Drugs market: report that lists top active companies as AstraZeneca, Merck, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, and Lupin Pharmaceuticals.

Research analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

Request a sample copy of Dyslipidemia Drugs Market Research Report @ https://marketsizeforecasters.com/get-sample/18310

Commenting on the report, an analyst team said: One trend in market is increasing use of statins. Statins dominate the global dyslipidemia drugs market. Statins are reported to be the most effective among all dyslipidemia drugs in lowering the risk of heart attacks. The ATP IV guidelines, which are based on data from randomized controlled trials, strongly recommend the use of statins to manage atherosclerotic CVD. The ATP IV guidelines have identified four treatment groups for statins and have recommended treatment based on intensity groups. For instance, it recommends the use of high-intensity statins in individuals with established atherosclerotic CVD. The other two intensity groups include moderate-intensity statin therapy and low-intensity statin therapy. Furthermore, the ATP IV panel found no evidence in support of using non-statin cholesterol-lowering drugs in individuals with statin intolerance or as a component of combination therapy. Moreover, the current ATP guidelines might not support the use of non-statin therapy in statin-tolerant patients.

The listed pricing for this Dyslipidemia Drugs Market report starts at $ 3500.
Request Discount for Dyslipidemia Drugs Market Research Report @ https://marketsizeforecasters.com/enquire-for-discount/18310

According to the report, one driver in market is increasing risk of CVDs. Elevated levels of cholesterol in the blood lead to the deposition of cholesterol in the arterial walls, which results in atherosclerosis, hardening and narrowing the arteries. The resultant narrowing of blood vessels decreases the blood flow to the heart muscles, causing a heart attack. High cholesterol levels account for nearly one-third of all ischemic heart diseases and hence, remain a significant cause of ischemic heart diseases and strokes in developed and developing countries such as India and China. Data estimates suggest that among men aged 40 years and over, a 10% decrease in serum cholesterol levels reduces the risk of heart disease by 50% within five years. Hence, cardiovascular risk management guidelines by authorities such as the American College of Cardiology and American Heart Association consider reducing blood cholesterol an important factor in reducing cardiovascular risk. As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD. This preventive approach toward the occurrence of CVDs will further boost the sales of cholesterol controlling agents.

Further, the report states that one challenge in market is drawbacks associated with current therapies. Statins are prescribed drugs for lowering LDL-C levels and constitute the first line of therapy for hypercholesterolemia. However, long-term administration and the muscle-related side effects of statins lead to poor patient compliance. Doubling the dose of statins might increase drug toxicity with a negligible increase in LDL-lowering effects. Furthermore, in February 2012, the FDA announced that statins could be associated with side effects such as cognitive effects and hyperglycemia. Bile acid sequestrates lead to side effects related to the gastrointestinal tract. Niacin-based formulations are generally associated with flushing and hepatotoxicity. Fibrates are associated with an increased risk of cholesterol gallstones and side effects related to the gastrointestinal tract. Thus, there is a high demand for lipid-lowering drugs with a good safety profile.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Browse full table of contents and data tables For Dyslipidemia Drugs Market Report of 70 pages https://marketsizeforecasters.com/global-dyslipidemia-drugs-market

Related Reports: -
Global Narcolepsy Drug Market by Manufacturers, Countries, Type and Application, Forecast to 2022
Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds...

MarketSizeForecasters.com, a Skyline Market Research LLP brand, is an online aggregator of market research reports. MarketSizeForecasters.com offers a comprehensive collection of full length reports on global and regional markets in 100+ industry verticals. We have partnered with some of the leading business and market research publishing houses and regularly update our online library to offer wide range of reports to our customers.

Market size forecasters
The Green Suite #4594,
Dover, DE 19901
United States
Phone: 1-201-355-0868
US Toll Free: 1-866-764-2150
Email: sales@marketsizeforecasters.com
Website: http://marketsizeforecasters.com/

This release was published on openPR.